Personalized CAR T-cell therapy was developed in the Doug Mahoney, left, lab for Calgarian Milan Heck. Arnie Charbonneau Cancer Institute
Personalized CAR T-cell therapy was developed in the Doug Mahoney, left, lab for Calgarian Milan Heck. Arnie Charbonneau Cancer Institute Idea generates local and national collaborations, a philanthropic gift toward a new research centre and an entrepreneurial opportunity Dr. Franz Zemp, PhD, gets chills talking about how his idea to target a specific cancer cell has evolved. "I never thought I'd be that close to a patient. I never thought anything that I would build, or design would be in a clinical trial," says Zemp, an adjunct assistant professor at the Cumming School of Medicine (CSM). "I would imagine it is every medical scientist's dream to build something or be part of something that could help somebody someday." Zemp designed a chimeric antigen receptor (CAR) T-cell therapy to attack alveolar soft part sarcoma (ASPS) for Calgarian Milan Heck. In 2015, Heck was a patient at the Alberta Children's Hospital. After undergoing the initial resection of the sarcoma in her hip, she was approached to donate samples of her cancer to the Clark H. Smith Tumour and Tissue bank at the University of Calgary.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
